[CLSTR]
< Back to situations

[PERSON]

Semaglutide

Featured in 19 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

313 clusters · 1156 sources · last updated

Latest: L’Oreal reports weight loss drugs are impacting beauty sales

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health. Cardiovascular benefits rema

[ACTIVE] [HEALTH] [US] [BR] [DK]

Novo Nordisk pivots strategy to counter patent cliff

112 clusters · 548 sources · last updated

Latest: Novo Nordisk faces intense competition in obesity drug market

Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,

[ACTIVE] [HEALTH] [US] [GB] [SE]

Expanding therapeutic uses and regulatory approvals for GLP-

33 clusters · 154 sources · last updated

Latest: GLP-1 medications show weight loss challenges regarding muscle mass and maintenance

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

Also covered in